Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 With or Without Nab-paclitaxel in Recurrent or Metastatic Triple-negative Breast Cancer
CTR20254817Phase 2Active
- Sponsor
- Leads Biolabs
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in triple-negative breast cancer (TNBC), sponsored by Leads Biolabs. Started Feb 2026; status: active.
02
Drugs
opamtistomig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20254817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254817.